ProCE Banner Activity

ARASENS: Post Hoc Analysis of Outcomes by Disease Volume and Risk With Darolutamide vs Placebo in Combination With ADT + Docetaxel in Metastatic HSPC

Capsule Summary
Conference Coverage
Slideset

The addition of darolutamide to ADT and docetaxel for mHSPC provided a significant OS benefit and improvements in multiple clinical secondary endpoints regardless of disease volume or risk status.

Released: February 22, 2023

Expiration: February 21, 2024

No longer available for credit.

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.